Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 11:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,525 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: placebo (saline) Clear all
Terminated Phase 4 Interventional Results available

Suprainguinal Fascia Iliaca (SIFI) Block Improves Analgesia Following Total Hip Arthroplasty

NCT02933671
View directory record Official record
Conditions
Hip Osteoarthritis, Primary Total Hip Arthroplasty, Pain
Interventions
Suprainguinal fascia iliaca (SIFI) block, Sham block, Ropivacaine, Saline
Procedure · Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Sep 23, 2026, 11:41 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation

NCT03110900
View directory record Official record
Conditions
Agitation,Psychomotor, Haloperidol Causing Adverse Effects in Therapeutic Use, Lorazepam Causing Adverse Effects in Therapeutic Use, Loxapine Causing Adverse Effects in Therapeutic Use
Interventions
Haloperidol + lorazepam, Loxapine
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2018 · Synced Sep 23, 2026, 11:41 AM EDT
Terminated Early Phase 1 Interventional Results available

Low Dose Vasopressin in Traumatic Shock

NCT00420407
View directory record Official record
Conditions
Injuries, Shock, Traumatic
Interventions
normal saline control, vasopressin
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2019 · Synced Sep 23, 2026, 11:41 AM EDT
Not listed Not applicable Interventional

Efficacy of IV Acetaminophen in Acute Post-Operative Pain Control in Laparoscopic Roux-en-Y Gastric Bypass Surgery (LRYGBP) Patients

NCT01460667
View directory record Official record
Conditions
Morbid Obesity
Interventions
IV acetaminophen, IV normal saline
Drug
Lead sponsor
McLaren Regional Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Flint, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 26, 2011 · Synced Sep 23, 2026, 11:41 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral Therapy

NCT05612178
View directory record Official record
Conditions
HIV-1
Interventions
3BNC117-LS, 10-1074-LS, Sterile Saline
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Bethesda, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 23, 2026, 11:41 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

NCT01258608
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Mapatumumab, Placebo, Sorafenib
Drug
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
9
States / cities
Aurora, Colorado • Shreveport, Louisiana • Rochester, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2018 · Synced Sep 23, 2026, 11:41 AM EDT
Terminated Phase 1 Interventional Results available

Multiple Dose Study Of PF-05231023 In Obese Adult Subjects

NCT01923389
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
Placebo, 100 mg PF-05231023
Other · Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
2
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Sep 23, 2026, 11:41 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Effect of Monosodium Glutamate on Microbiome-Derived Imidazole Propionate Production in Healthy Volunteers

NCT07700368
View directory record Official record
Conditions
Healthy Adult
Interventions
L-histidine, Monosodium glutamate (MSG), Sodium chloride (NaCl)
Dietary Supplement
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 23, 2026, 11:41 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of FX006 in Patients With Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis

NCT04160091
View directory record Official record
Conditions
Osteoarthritis of the Shoulder, Adhesive Capsulitis
Interventions
FX006, Normal Saline
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
35 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
27
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Sep 23, 2026, 11:41 AM EDT
Completed Phase 1Phase 2 Interventional Results available

The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity

NCT03119610
View directory record Official record
Conditions
Obesity, Sarcopenic Obesity, Sarcopenia, Aging, Sedentary Lifestyle
Interventions
Oxytocin nasal spray, Placebo nasal spray
Drug
Lead sponsor
Sara Espinoza
Other
Eligibility
60 Years to 99 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Sep 23, 2026, 11:41 AM EDT
Terminated Phase 1Phase 2 Interventional

Mesenchymal Stem Cells for the Treatment of Rectovaginal Fistulas in Participants With Crohn's Disease

NCT04519697
View directory record Official record
Conditions
Rectovaginal Fistula, Crohn Disease, Crohn Disease of Vulva, Rectolabial; Fistula
Interventions
Mesenchymal Stem Cells, Placebo
Drug · Other
Lead sponsor
Anthony Lembo
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 23, 2026, 11:41 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma

NCT05322590
View directory record Official record
Conditions
Metastatic Colorectal Carcinoma, Neuropathy
Interventions
BXQ-350, Placebo
Drug · Other
Lead sponsor
Bexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
12
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Sep 23, 2026, 11:41 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection

NCT01134510
View directory record Official record
Conditions
Kidney Transplantation
Interventions
C1 Esterase Inhibitor, Placebos
Drug
Lead sponsor
Stanley Jordan, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Sep 23, 2026, 11:41 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Dose Response of Epinephrine

NCT02692313
View directory record Official record
Conditions
Diabetes Complications
Interventions
Epinephrine, Saline infusion
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Sep 23, 2026, 11:41 AM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer

NCT03241810
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Seribantumab, Fulvestrant, Placebo
Drug
Lead sponsor
Elevation Oncology
Industry
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
22
States / cities
Chandler, Arizona • Fayetteville, Arkansas • Beverly Hills, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Sep 23, 2026, 11:41 AM EDT
Completed Phase 3 Interventional Results available

Hydrocortisone for BPD

NCT01353313
View directory record Official record
Conditions
Infant, Newborn, Infant, Small for Gestational Age, Infant, Very Low Birth Weight, Infant, Premature, Bronchopulmonary Dysplasia
Interventions
Hydrocortisone, Placebo
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 30 Weeks
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Sep 23, 2026, 11:41 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

RCT Comparing ESWT With PRP for Plantar Fasciitis in High Demand Cohort

NCT02668510
View directory record Official record
Conditions
Fasciitis, Plantar
Interventions
platelet rich plasma, Normal saline
Biological · Drug
Lead sponsor
Edna Rath
Federal
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Sep 23, 2026, 11:41 AM EDT
Completed Not applicable Interventional Results available

Short-Term Application of Tocilizumab Following Myocardial Infarction

NCT02419937
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Tocilizumab, Placebo
Drug
Lead sponsor
Keesler Air Force Base Medical Center
Federal
Eligibility
18 Years to 89 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Keesler Air Force Base, Mississippi
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Sep 23, 2026, 11:41 AM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

What is the Role of Type III/IV Muscle Afferents in Airway Resistance and Thermoregulatory Responses to Exercise?

NCT07452094
View directory record Official record
Conditions
Placebo - Control, Experimental
Interventions
EXERCISE TRAINING WITH OR WITHOUT MEDICATION
Drug
Lead sponsor
Northern Arizona University
Other
Eligibility
18 Years to 40 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Flagstaff, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 23, 2026, 11:41 AM EDT
Recruiting Phase 2 Interventional

Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients

NCT07223229
View directory record Official record
Conditions
Non-segmental Vitiligo
Interventions
EI-001, Placebo
Biological · Other
Lead sponsor
Elixiron Immunotherapeutics (Hong Kong) Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Huntington Beach, California • Hollywood, Florida • Worcester, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 23, 2026, 11:41 AM EDT
Completed Not applicable Interventional Results available

Pilot Feasibility Study of the Safety and Efficacy of Anakinra in Heart Failure With Preserved Ejection Fraction

NCT01542502
View directory record Official record
Conditions
Heart Failure
Interventions
Anakinra, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 5, 2017 · Synced Sep 23, 2026, 11:41 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction

NCT04463251
View directory record Official record
Conditions
Acute ST Segment Elevation Myocardial Infarction
Interventions
RPH-104 80 mg, Placebo
Biological · Drug
Lead sponsor
R-Pharm Overseas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Cleveland, Ohio • Charlottesville, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 23, 2024 · Synced Sep 23, 2026, 11:41 AM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults

NCT07675629
View directory record Official record
Conditions
HIV Prevention
Interventions
PDPHV Plasmid DNA Vaccines (env (A, B, C, A/E)/gag (C)), PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E)), Alhydrogel adjuvant, GLA-SE adjuvant, Placebo for DNA Vaccines, Protein Vaccines and Adjuvants
Biological
Lead sponsor
Worcester HIV Vaccine
Industry
Eligibility
18 Years to 55 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 23, 2026, 11:41 AM EDT
Terminated Phase 2 Interventional Results available

CD40L Antagonism in Rheumatoid Arthritis (RA)

NCT05306353
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo for VIB4920, VIB4920 with TNFi, VIB4920 without TNFi
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
San Francisco, California • Aurora, Colorado • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 23, 2026, 11:41 AM EDT